Bunionectomy Study - Full Text View

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00601458

Purpose

We are interested in whether bunionectomy can be used as a model to study the treatment of acute pain. It has been used to study the effect of Non-Steroidal Anti-inflammatory (NSAIDS) medications (such as ibuprofen) and other pain relieving drugs. We are interested to know if this model is useful to study other drugs for the treatment of acute pain. The other drugs being tested in this study are pregabalin and naproxen sodium. These drugs are approved for use by the Food and Drug Administration (FDA). This study is designed to test whether these two drugs are effective in treating pain after a bunionectomy.

Condition	Intervention	Phase
Acute Pain	Drug: pregabalin Drug: naproxen sodium Drug: Comparator: Placebo	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Pregabalin and Naproxen Sodium on Postoperative Pain After Bunionectomy

Resource links provided by NLM:

Drug Information available for: Naproxen Naproxen sodium Pregabalin

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery [ Time Frame: First 24 hours following surgery ] [ Designated as safety issue: No ]
Total dose (amount) of hydromorphone via patient controlled analgesic (PCA) pump required in the 24 hours post-surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.

Secondary Outcome Measures:

Time to First Request of PCA Hydromorphone [ Time Frame: First 24 hours following surgery ] [ Designated as safety issue: No ]
Time (in hours) to first patient controlled analgesic (PCA) pump use after surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.

Enrollment:	100
Study Start Date:	July 2007
Study Completion Date:	February 2008
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Arm 1: Pregabalin 300 mg	Drug: pregabalin Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0. Other Name: pregabalin
Active Comparator: Arm 2: naproxen sodium 550 mg	Drug: naproxen sodium Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0. Other Name: naproxen
Placebo Comparator: Arm 3: Placebo	Drug: Comparator: Placebo Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient is a man or woman between 18 and 65 years of age
For Women of Child-bearing potential: woman who is currently not pregnant not nursing and who is willing to use a medically acceptable method of birth control from the time after the screening visit until completion of the follow-up visit
Patient is scheduled to have a bunionectomy
Patient must be willing to stay at the study site throughout the 48-hour observation period following surgery and is willing to complete a 2-week follow up
Patient is capable of operating a Patient Controlled Analgesia device

Exclusion Criteria:

Patient is being treated for a disease and has not been on a stable dose of medication for at least 2 weeks prior to surgery
Patient has used or intends to use any of the medications that are prohibited by the protocol, which could interfere with the evaluation of the study drugs
Patient has an estimated creatinine clearance of < or = 60 mL per min
Patient has a history of drug abuse or dependence, or patient has a positive urine drug screen
Patient has a condition that prevents clear communication concerning pain perception (such as diabetic neuropathy, peripheral neuropathy, etc.)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00601458

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

Responsible Party:	Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier:	NCT00601458 History of Changes
Other Study ID Numbers:	2007_661, 063
Study First Received:	January 15, 2008
Results First Received:	December 23, 2009
Last Updated:	April 13, 2010
Health Authority:	United States: Food and Drug Administration

Keywords provided by Merck:

Primary, unilateral, first metatarsal bunionectomy with osteotomy

Additional relevant MeSH terms:

Naproxen
Pregabalin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions

Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on February 09, 2012